Business
Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year
Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year.
About this update from Neutra Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Neutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year\r\n \r\n \r\n\r\n\r\nNeutra Corp Successfully Pivots Into New Business Vertical With Projected Over 1,000% Revenue Increase Year-Over-Year\r\n\r\n\r\n\r\n\r\n\r\nHOUSTON, TX - January 19, 2026 (NEWMEDIAWIRE) - Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a successful strategic pivot into the clinical research industry, resulting in a projected revenue increase of more than 1,000% year-over-year. This growth is driven by the launch and rapid expansion of its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). \r\n Neutra Life Sciences was established to address the growing demand for high-quality, compliant, and scalable clinical trial site operations. Since its formation, the subsidiary has executed multiple site partnerships, expanded its investigator network, and initiated new clinical studies across several therapeutic areas. \r\n As part of its 2025 pivot, Neutra Life Sciences participated in Parexels Emerging Site Scholarship Program and was selected as one of the Emerging Site Partners. This positions Neutra Life Sciences among a select group of sites receiving targeted operational support, specialized training, and enhanced access to global clinical trial opportunities. The program is designed to strengthen research capacity, improve regulatory readiness, and expand each sites ability to participate in innovative and high-impact clinical studies. \r\n We are honored to have Neutra Life Sciences chosen by Parexel for this prestigious partnership, said Sydney Jim, President and CEO of Neutra Life Sciences. This collaboration validates our commitment to advancing clinical research and expanding our capabilities in life sciences. Working alongside Parexel will accelerate our growth, elevate our research infrastructure, and open doors to more trials. \r\n Through this partnership, Neutra Life Sciences will benefit from: \r\n Operational mentorship and hands-on site development support \r\n Access to training and professional development for clinical staff \r\n Increased exposure to global clinical trial sponsors \r\n Opportunities to participate in cutting-edge, high-value clinical researc...